<p>隨着全球市場表現不一，日本股市下跌，而中國製造業部門顯示出適度改善，投資者越來越關注亞洲股票中的潛在機會。在這種環境下，識別被低估的股票可以是一項戰略性舉措，因為這些投資在市場條件穩定或改善時可能提供顯著的上行潛力。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>藥明 XDC 開曼（SEHK:2268）</td>
<td>HK$68.50</td>
<td>HK$135.26</td>
<td>49.4%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥10040.00</td>
<td>¥19790.82</td>
<td>49.3%</td>
</tr>
<tr>
<td>蘇州澤璟生物製藥（SHSE:688266）</td>
<td>CN¥99.90</td>
<td>CN¥199.49</td>
<td>49.9%</td>
</tr>
<tr>
<td>中科醫療科技（SHSE:688108）</td>
<td>CN¥21.89</td>
<td>CN¥43.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream（TSE:4587）</td>
<td>¥1738.00</td>
<td>¥3437.58</td>
<td>49.4%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1619.00</td>
<td>¥3157.04</td>
<td>48.7%</td>
</tr>
<tr>
<td>Fositek（TWSE:6805）</td>
<td>NT$1405.00</td>
<td>NT$2741.10</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥797.00</td>
<td>¥1580.29</td>
<td>49.6%</td>
</tr>
<tr>
<td>ASE 科技控股（TWSE:3711）</td>
<td>NT$275.00</td>
<td>NT$540.37</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology（TWSE:6533）</td>
<td>NT$247.00</td>
<td>NT$481.04</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 261 只被低估亞洲股票的完整列表。</p>
<p>以下是篩選器中一些選擇的預覽。</p>
<h2>南京領先生物實驗室（SEHK:9887）</h2>
<p><strong>概述：</strong> 南京領先生物實驗室有限公司是一家臨牀階段的生物技術公司，專注於全球新型抗體藥物的研究、開發和商業化，市值為 HK$111.4 億。</p>
<p><strong>運營：</strong> 南京領先生物實驗室有限公司主要通過全球範圍內創新抗體藥物的研究、開發和商業化來產生收入。</p>
<p><strong>公允價值折扣估算：</strong> 25.7%</p>
<p>南京領先生物實驗室的交易價格為 HK$56，低於其估算的公允價值 HK$75.33，表明基於現金流的低估。公司預計在三年內實現盈利，年預測收益增長為 40.72%，年收入增長為 55.8%，超過香港市場平均水平。近期的合作和臨牀進展增強了其應對自身免疫疾病的潛力，進一步支持其在持續產品開發和高達 10 億美元的戰略合作伙伴關係中的財務前景。</p>
<ul>
<li>根據我們最近的增長報告，南京領先生物實驗室的財務表現可能會超過當前水平。</li>
<li>點擊這裏瞭解南京領先生物實驗室的詳細財務健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:9887 截至 2026 年 1 月的折現現金流</p>
<h2>中科醫療科技（SHSE:688108）</h2>
<p><strong>概述：</strong> 中科醫療科技股份有限公司是一家中國醫療器械公司，專注於介入醫療器械的研究、開發、生產和分銷，市值約為 CN¥91.1 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其醫療產品部門，產生了 CN¥5.0411 億的收入。</p>
<p><strong>公允價值折扣估算：</strong> 49.6%</p>
<p>中科醫療科技的交易價格為 CN¥21.89，顯著低於其估算的公允價值 CN¥43.45，突顯出基於現金流的低估。公司最近實現盈利，2025 年 9 月止的九個月內淨收入為 CNY 2112 萬，扭轉了之前的虧損。預計未來三年內收益將大幅增長，年增長率為 63.5%，超過中國市場的平均增長率，儘管股價波動和低預測股本回報率，但仍支持其投資吸引力。</p>
<ul>
<li>我們的增長報告顯示，中科醫療科技可能正處於改善前景的階段。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解中科醫療科技的動態。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688108 截至 2026 年 1 月的折現現金流</p>
<h2>深圳新威光掩膜製造（SHSE:688401）</h2>
<p><strong>概述：</strong> 深圳新威光掩膜製造有限公司是一家專注於中國掩膜產品設計、開發和生產的光刻公司，市值為 CN¥104.7 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其電子元件及零部件部門，總計 CN¥11 億。</p>
<p><strong>公允價值折扣估算：</strong> 31.5%</p>
<p>深圳新威光掩膜製造的價格為 CN¥54.7，交易價格低於其估算的公允價值 CN¥79.83，表明基於現金流的低估。公司過去一年收益增長了 49.6%，截至 2025 年 9 月的九個月內淨收入達到 CNY 171.76 萬。儘管股價波動和自由現金流的低股息覆蓋率，但未來收入和收益預計將顯著高於市場平均水平，增強其投資前景。</p>
<ul>
<li>我們精心準備的深圳新威光掩膜製造增長報告暗示其未來財務前景可能比近期結果更強。</li>
<li>在這份財務健康報告中解鎖我們對深圳新威光掩膜製造股票分析的全面見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688401 截至 2026 年 1 月的折現現金流</p>
<h2>總結</h2>
<ul>
<li>點擊此鏈接深入瞭解我們基於現金流的被低估亞洲股票篩選器中的 261 家公司。</li>
<li>是這些公司的股東嗎？確保您不會被突發情況所困擾，通過在 Simply Wall St 中添加您的投資組合，以便及時獲得重大股票動態的提醒。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用程序，免費且覆蓋全球所有市場。</li>
</ul>
<h2>準備好嘗試不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅股來分散您的投資組合，以應對潛在的市場波動。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

澤璟制藥-U

<p>隨着全球市場表現參差不齊，投資者正將目光投向被低估的亞洲股票。值得注意的包括吳曉波 XDC 開曼、Visional 和蘇州澤璟製藥，公允價值的折扣高達 49.9%。南京領航生物實驗室和中科醫療科技等公司因其增長潛力而受到關注，預計將實現顯著的盈利增長。文章強調在當前市場環境下投資這些被低估股票的戰略優勢，暗示隨着市場的穩定，可能會帶來可觀的回報</p>

<p>As global markets experience mixed performances, with Japan's stock markets declining and China's manufacturing sector showing modest improvement, investors are increasingly turning their attention to the potential opportunities within Asian equities. In this environment, identifying undervalued stocks can be a strategic move, as these investments may offer significant upside potential when market conditions stabilize or improve.</p>
<div class="lb-trans"><p>隨着全球市場表現不一，日本股市下跌，而中國製造業部門顯示出適度改善，投資者越來越關注亞洲股票中的潛在機會。在這種環境下，識別被低估的股票可以是一項戰略性舉措，因為這些投資在市場條件穩定或改善時可能提供顯著的上行潛力。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>WuXi XDC Cayman (SEHK:2268)</td>
<td>HK$68.50</td>
<td>HK$135.26</td>
<td>49.4%</td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10040.00</td>
<td>¥19790.82</td>
<td>49.3%</td>
</tr>
<tr>
<td>Suzhou Zelgen Biopharmaceuticals (SHSE:688266)</td>
<td>CN¥99.90</td>
<td>CN¥199.49</td>
<td>49.9%</td>
</tr>
<tr>
<td>Sino Medical Sciences Technology (SHSE:688108)</td>
<td>CN¥21.89</td>
<td>CN¥43.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1738.00</td>
<td>¥3437.58</td>
<td>49.4%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1619.00</td>
<td>¥3157.04</td>
<td>48.7%</td>
</tr>
<tr>
<td>Fositek (TWSE:6805)</td>
<td>NT$1405.00</td>
<td>NT$2741.10</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥797.00</td>
<td>¥1580.29</td>
<td>49.6%</td>
</tr>
<tr>
<td>ASE Technology Holding (TWSE:3711)</td>
<td>NT$275.00</td>
<td>NT$540.37</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$247.00</td>
<td>NT$481.04</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>藥明 XDC 開曼（SEHK:2268）</td>
<td>HK$68.50</td>
<td>HK$135.26</td>
<td>49.4%</td>
</tr>
<tr>
<td>Visional（TSE:4194）</td>
<td>¥10040.00</td>
<td>¥19790.82</td>
<td>49.3%</td>
</tr>
<tr>
<td>蘇州澤璟生物製藥（SHSE:688266）</td>
<td>CN¥99.90</td>
<td>CN¥199.49</td>
<td>49.9%</td>
</tr>
<tr>
<td>中科醫療科技（SHSE:688108）</td>
<td>CN¥21.89</td>
<td>CN¥43.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>PeptiDream（TSE:4587）</td>
<td>¥1738.00</td>
<td>¥3437.58</td>
<td>49.4%</td>
</tr>
<tr>
<td>Kuraray（TSE:3405）</td>
<td>¥1619.00</td>
<td>¥3157.04</td>
<td>48.7%</td>
</tr>
<tr>
<td>Fositek（TWSE:6805）</td>
<td>NT$1405.00</td>
<td>NT$2741.10</td>
<td>48.7%</td>
</tr>
<tr>
<td>CURVES HOLDINGS（TSE:7085）</td>
<td>¥797.00</td>
<td>¥1580.29</td>
<td>49.6%</td>
</tr>
<tr>
<td>ASE 科技控股（TWSE:3711）</td>
<td>NT$275.00</td>
<td>NT$540.37</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology（TWSE:6533）</td>
<td>NT$247.00</td>
<td>NT$481.04</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 261 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 261 只被低估亞洲股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的預覽。</p>
</div><h2>Nanjing Leads Biolabs (SEHK:9887)</h2>
<div class="lb-trans"><h2>南京領先生物實驗室（SEHK:9887）</h2>
</div><p><strong>Overview:</strong> Nanjing Leads Biolabs Co., Ltd. is a clinical-stage biotechnology company focused on the research, development, and commercialization of novel antibody drugs globally, with a market cap of HK$11.14 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 南京領先生物實驗室有限公司是一家臨牀階段的生物技術公司，專注於全球新型抗體藥物的研究、開發和商業化，市值為 HK$111.4 億。</p>
</div><p><strong>Operations:</strong> Nanjing Leads Biolabs Co., Ltd. generates its revenue primarily through the research, development, and commercialization of innovative antibody drugs on a global scale.</p>
<div class="lb-trans"><p><strong>運營：</strong> 南京領先生物實驗室有限公司主要通過全球範圍內創新抗體藥物的研究、開發和商業化來產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 25.7%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 25.7%</p>
</div><p>Nanjing Leads Biolabs is trading at HK$56, below its estimated fair value of HK$75.33, suggesting undervaluation based on cash flows. The company anticipates becoming profitable in three years with forecasted earnings growth of 40.72% annually and revenue growth of 55.8% per year, surpassing the Hong Kong market average. Recent collaborations and clinical advancements enhance its potential for addressing autoimmune diseases, further supporting its financial outlook amidst ongoing product developments and strategic partnerships valued up to $1 billion.</p>
<div class="lb-trans"><p>南京領先生物實驗室的交易價格為 HK$56，低於其估算的公允價值 HK$75.33，表明基於現金流的低估。公司預計在三年內實現盈利，年預測收益增長為 40.72%，年收入增長為 55.8%，超過香港市場平均水平。近期的合作和臨牀進展增強了其應對自身免疫疾病的潛力，進一步支持其在持續產品開發和高達 10 億美元的戰略合作伙伴關係中的財務前景。</p>
</div><ul>
<li>In light of our recent growth report, it seems possible that Nanjing Leads Biolabs' financial performance will exceed current levels.</li>
<li>Click here to discover the nuances of Nanjing Leads Biolabs with our detailed financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們最近的增長報告，南京領先生物實驗室的財務表現可能會超過當前水平。</li>
<li>點擊這裏瞭解南京領先生物實驗室的詳細財務健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/bd862d05-a4c6-494f-bbcf-5b9a803ad2dd/chart/dcf?theme=light"/></p>
<p>SEHK:9887 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:9887 截至 2026 年 1 月的折現現金流</p>
</div><h2>Sino Medical Sciences Technology (SHSE:688108)</h2>
<div class="lb-trans"><h2>中科醫療科技（SHSE:688108）</h2>
</div><p><strong>Overview:</strong> Sino Medical Sciences Technology Inc. is a Chinese medical device company focused on the research, development, production, and distribution of interventional medical devices, with a market cap of approximately CN¥9.11 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中科醫療科技股份有限公司是一家中國醫療器械公司，專注於介入醫療器械的研究、開發、生產和分銷，市值約為 CN¥91.1 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its medical products segment, which generated CN¥504.11 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其醫療產品部門，產生了 CN¥5.0411 億的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 49.6%</p>
</div><p>Sino Medical Sciences Technology is trading at CN¥21.89, significantly below its estimated fair value of CN¥43.45, highlighting undervaluation based on cash flows. The company recently turned profitable with a net income of CNY 21.12 million for the nine months ending September 2025, reversing a prior loss. Earnings are projected to grow substantially at 63.5% annually over the next three years, outpacing the Chinese market average growth rate and supporting its investment appeal despite share price volatility and low forecasted return on equity.</p>
<div class="lb-trans"><p>中科醫療科技的交易價格為 CN¥21.89，顯著低於其估算的公允價值 CN¥43.45，突顯出基於現金流的低估。公司最近實現盈利，2025 年 9 月止的九個月內淨收入為 CNY 2112 萬，扭轉了之前的虧損。預計未來三年內收益將大幅增長，年增長率為 63.5%，超過中國市場的平均增長率，儘管股價波動和低預測股本回報率，但仍支持其投資吸引力。</p>
</div><ul>
<li>Our growth report here indicates Sino Medical Sciences Technology may be poised for an improving outlook.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Sino Medical Sciences Technology.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的增長報告顯示，中科醫療科技可能正處於改善前景的階段。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解中科醫療科技的動態。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/4dcbc027-94ee-4d25-a685-860056d22101/chart/dcf?theme=light"/></p>
<p>SHSE:688108 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688108 截至 2026 年 1 月的折現現金流</p>
</div><h2>Shenzhen Newway Photomask Making (SHSE:688401)</h2>
<div class="lb-trans"><h2>深圳新威光掩膜製造（SHSE:688401）</h2>
</div><p><strong>Overview:</strong> Shenzhen Newway Photomask Making Co., Ltd is a lithography company focused on the design, development, and production of mask products in China with a market cap of CN¥10.47 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 深圳新威光掩膜製造有限公司是一家專注於中國掩膜產品設計、開發和生產的光刻公司，市值為 CN¥104.7 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Electronic Components &amp; Parts segment, totaling CN¥1.10 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其電子元件及零部件部門，總計 CN¥11 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 31.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 31.5%</p>
</div><p>Shenzhen Newway Photomask Making, priced at CN¥54.7, is trading 31.5% below its estimated fair value of CN¥79.83, indicating undervaluation based on cash flows. The company's earnings grew by 49.6% over the past year with net income reaching CNY 171.76 million for the nine months ending September 2025. Despite share price volatility and a low dividend coverage by free cash flow, future revenue and earnings are forecast to grow significantly above market averages, enhancing its investment prospects.</p>
<div class="lb-trans"><p>深圳新威光掩膜製造的價格為 CN¥54.7，交易價格低於其估算的公允價值 CN¥79.83，表明基於現金流的低估。公司過去一年收益增長了 49.6%，截至 2025 年 9 月的九個月內淨收入達到 CNY 171.76 萬。儘管股價波動和自由現金流的低股息覆蓋率，但未來收入和收益預計將顯著高於市場平均水平，增強其投資前景。</p>
</div><ul>
<li>Our expertly prepared growth report on Shenzhen Newway Photomask Making implies its future financial outlook may be stronger than recent results.</li>
<li>Unlock comprehensive insights into our analysis of Shenzhen Newway Photomask Making stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們精心準備的深圳新威光掩膜製造增長報告暗示其未來財務前景可能比近期結果更強。</li>
<li>在這份財務健康報告中解鎖我們對深圳新威光掩膜製造股票分析的全面見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8d1cc564-fd39-47ce-af9c-a903bd68d5b8/chart/dcf?theme=light"/></p>
<p>SHSE:688401 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688401 截至 2026 年 1 月的折現現金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Click this link to deep-dive into the 261 companies within our Undervalued Asian Stocks Based On Cash Flows screener.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們基於現金流的被低估亞洲股票篩選器中的 261 家公司。</li>
<li>是這些公司的股東嗎？確保您不會被突發情況所困擾，通過在 Simply Wall St 中添加您的投資組合，以便及時獲得重大股票動態的提醒。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用程序，免費且覆蓋全球所有市場。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好嘗試不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅股來分散您的投資組合，以應對潛在的市場波動。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

3 只亞洲股票被認為低估了高達 49.6%